Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19
Transboundary and Emerging Diseases · 2024-01 · 2024 (1)
DOI: 10.1155/2024/5566180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, online erschienen am 05.02.2024. Verfasst von Suhas Krishnamoorthy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. Hauptthemen laut MEDLINE: COVID-19, Proteome, Blood Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JULAC 2023.
Abstract (Originalsprache)
Background
The COVID‐19 pandemic caused by the SARS‐CoV‐2 virus has resulted in a global health crisis with significant morbidity and mortality. While effective vaccinations have been developed, drug treatments for the disease are still required, particularly for different stages of the disease and to combat evolving variants. Identifying reliable biomarkers and potential therapeutic targets for the different stages of COVID‐19 is crucial.
Methods
Mendelian randomization using the largest publicly available datasets was conducted to identify potential causal plasma proteins for severe COVID‐19, hospitalized COVID‐19, and SARS‐CoV‐2 infection. Independent, and strongly associated cis‐ or pan‐pQTLs were used as instrumental variables for each protein. The FDR q ‐value was used to correct for multiple testing followed by sensitivity analyses, reverse MR and genetic colocalization to ensure the robustness of the results.
Results
We identified proteins with strong evidence of causal association with different stages of COVID‐19. Some of these proteins were identified previously, such as BGAT and BCAT2, but we also identified the novel proteins, such as KLC1, MRVI1, CACO2, and PCNP.
Conclusion
These proteins provide valuable insights into the underlying mechanisms of COVID‐19. The identification of these proteins offers new opportunities for developing potential therapeutic targets or biomarkers for the treatment and prevention of COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
ORCID-Profile: Ching Lung Cheung
Förderung
- JULAC 2023
Zitieren
APA
Krishnamoorthy, S., Hoo, R. L. C., & Cheung, C. L. (2024). Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19. Transboundary and Emerging Diseases, 2024(1). https://doi.org/10.1155/2024/5566180
Vancouver
Krishnamoorthy S, Hoo RLC, Cheung CL. Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19. Transboundary and Emerging Diseases. 2024;2024(1). doi:10.1155/2024/5566180
BibTeX
@article{Krishnamoorthy2024,
author = {Krishnamoorthy, Suhas and Hoo, Ruby Lai Chong and Cheung, Ching Lung},
title = {Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19},
journal = {Transboundary and Emerging Diseases},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/5566180}
}
EUVIMED